Zimmer Biomet (NYSE:ZBH) Given New $98.00 Price Target at Wells Fargo & Company

Zimmer Biomet (NYSE:ZBH) had its target price upped by Wells Fargo & Company from $93.00 to $98.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an equal weight rating on the medical equipment provider’s stock.

A number of other equities analysts also recently issued reports on ZBH. The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research report on Friday, January 9th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Johnson Rice set a $112.00 price target on Zimmer Biomet in a research note on Wednesday, November 5th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday. Finally, Barclays reduced their target price on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Trading Up 1.3%

Shares of NYSE ZBH traded up $1.23 during mid-day trading on Wednesday, hitting $96.84. 508,181 shares of the company traded hands, compared to its average volume of 2,343,494. The business has a 50 day moving average of $90.01 and a two-hundred day moving average of $95.64. Zimmer Biomet has a 1 year low of $84.59 and a 1 year high of $114.44. The company has a quick ratio of 1.39, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $19.19 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 2.34 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period in the prior year, the company earned $2.31 EPS. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Tuesday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s payout ratio is currently 27.12%.

Institutional Trading of Zimmer Biomet

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. M&T Bank Corp lifted its stake in Zimmer Biomet by 15,705.6% in the 4th quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock valued at $321,158,000 after acquiring an additional 3,548,998 shares in the last quarter. Dodge & Cox raised its stake in Zimmer Biomet by 12.9% during the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after acquiring an additional 2,533,009 shares in the last quarter. Norges Bank acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $225,867,000. Franklin Resources Inc. grew its holdings in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after buying an additional 2,017,857 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after buying an additional 955,284 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback: ZBH reported Q4 EPS of $2.42 and revenue up ~11% YoY, beating estimates; management also announced a new share buyback, which together drove the immediate market rally. Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced
• Positive Sentiment: Analyst upgrade/positive call: BTIG reaffirmed a Buy and set a $112 price target, signaling conviction that the company’s orthopedic demand and margin recovery story have upside. Zimmer Biomet (NYSE:ZBH) Earns “Buy” Rating from BTIG Research
• Neutral Sentiment: Broker price target tweaks but cautious stance: Citigroup and Wells Fargo nudged their price targets to $98 while keeping neutral/equal-weight recommendations, implying only modest upside from current levels. Benzinga coverage of analyst price target changes
• Neutral Sentiment: Needham reaffirms Hold: Needham kept its Hold rating, reflecting mixed views on medium-term upside despite recent top-line strength. Needham & Company LLC Reaffirms “Hold” Rating for Zimmer Biomet (NYSE:ZBH)
• Negative Sentiment: Cautious guidance, margin pressure and operational reset risks: Management issued measured 2026 guidance and noted a U.S. salesforce overhaul that could weigh on near-term growth and margins; tariffs and margin contraction were called out as headwinds by analysts and in earnings commentary. ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.